IN2014DN09640A - - Google Patents
Info
- Publication number
- IN2014DN09640A IN2014DN09640A IN9640DEN2014A IN2014DN09640A IN 2014DN09640 A IN2014DN09640 A IN 2014DN09640A IN 9640DEN2014 A IN9640DEN2014 A IN 9640DEN2014A IN 2014DN09640 A IN2014DN09640 A IN 2014DN09640A
- Authority
- IN
- India
- Prior art keywords
- protein tyrosine
- tyrosine phosphatase
- disorder
- ptp
- precursors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/657163—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/657163—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom
- C07F9/657181—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom the ring phosphorus atom and, at least, one ring oxygen atom being part of a (thio)phosphonic acid derivative
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4021—Esters of aromatic acids (P-C aromatic linkage)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4056—Esters of arylalkanephosphonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261624572P | 2012-04-16 | 2012-04-16 | |
| PCT/CA2013/000364 WO2013155600A1 (en) | 2012-04-16 | 2013-04-16 | Fused aromatic phosphonate derivatives as precursors to ptp-1b inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN09640A true IN2014DN09640A (pl) | 2015-07-31 |
Family
ID=49382741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN9640DEN2014 IN2014DN09640A (pl) | 2012-04-16 | 2013-04-16 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20150057220A1 (pl) |
| EP (1) | EP2838906A4 (pl) |
| JP (1) | JP2015519309A (pl) |
| KR (1) | KR20140145624A (pl) |
| CN (1) | CN104411710A (pl) |
| AU (1) | AU2013248880A1 (pl) |
| CA (1) | CA2870488A1 (pl) |
| IL (1) | IL235081A0 (pl) |
| IN (1) | IN2014DN09640A (pl) |
| MX (1) | MX2014012465A (pl) |
| WO (1) | WO2013155600A1 (pl) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023220833A1 (en) * | 2022-05-19 | 2023-11-23 | Kanyr Pharma Inc. | Combined inhibition of tyrosine phosphatases tcptp and ptp1b and pd-1 blockage immunotherapy in the treatment of cancer |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US5545618A (en) | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
| AU1856997A (en) | 1996-02-02 | 1997-08-22 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
| AR008789A1 (es) | 1996-07-31 | 2000-02-23 | Bayer Corp | Piridinas y bifenilos substituidos |
| UA65549C2 (uk) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
| WO1998039344A1 (en) | 1997-03-07 | 1998-09-11 | Metabasis Therapeutics, Inc. | Novel purine inhibitors of fructose-1,6-bisphosphatase |
| US6054587A (en) | 1997-03-07 | 2000-04-25 | Metabasis Therapeutics, Inc. | Indole and azaindole inhibitors of fructose-1,6-bisphosphatase |
| DK0970095T3 (da) | 1997-03-07 | 2004-03-08 | Metabasis Therapeutics Inc | Hidtil ukendte benzimidazolinhibitorer for fructose-1,6-bisphosphase |
| US6613942B1 (en) | 1997-07-01 | 2003-09-02 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
| BR9810378A (pt) | 1997-07-01 | 2000-08-29 | Novo Nordisk As | Composto,uso do mesmo, composição farmacêutica, e, processos de tratar a diabete do tipo i ou do tipo ii, de tratar a hiperglicemia, e de diminuir a glicose do sangue em um mamìfero |
| CN1215076C (zh) | 1998-09-09 | 2005-08-17 | 症变治疗公司 | 新的果糖1,6－二磷酸酶的杂芳族抑制剂 |
| AU3033500A (en) | 1999-01-15 | 2000-08-01 | Agouron Pharmaceuticals, Inc. | Non-peptide glp-1 agonists |
| ES2225107T3 (es) | 1999-03-29 | 2005-03-16 | Uutech Limited | Analogos del peptido inhibidor gastrico y su uso para el tratamiento de la diabetes. |
| JP2002541146A (ja) | 1999-04-02 | 2002-12-03 | ニューロゲン コーポレイション | アリールおよびヘテロアリール融合のアミノアルキル−イミダゾール誘導体および糖尿病薬としてのその使用 |
| AU4537900A (en) | 1999-05-17 | 2000-12-05 | Agouron Pharmaceuticals, Inc. | Glucagon antagonists/inverse agonists |
| SK5552002A3 (en) | 1999-09-28 | 2003-05-02 | Bayer Ag | Pituitary adenylate cyclase activating peptide (PACAP) receptor 3 (R3) agonists and their pharmacological methods of use |
| AU4398801A (en) * | 2000-03-22 | 2001-10-03 | Banyu Pharmaceutical Co., Ltd. | Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors |
| DE60128475T2 (de) | 2000-07-25 | 2008-02-07 | Merck & Co., Inc. | N-substituierte indole mit anwendung in der behandlung von diabetes |
| WO2002060388A2 (en) | 2001-01-30 | 2002-08-08 | Merck & Co., Inc. | Acyl sulfamides for treatment of obesity, diabetes and lipid disorders |
| UA74912C2 (en) | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
| SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
| GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
| AR040241A1 (es) | 2002-06-10 | 2005-03-23 | Merck & Co Inc | Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia |
| CA2495915A1 (en) | 2002-08-29 | 2004-03-11 | Merck & Co., Inc. | Indoles having anti-diabetic activity |
| WO2004020409A1 (en) | 2002-08-29 | 2004-03-11 | Merck & Co., Inc. | Indoles having anti-diabetic activity |
| JO2397B1 (en) | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
| AU2004207444B2 (en) | 2003-01-17 | 2008-07-31 | Merck & Co., Inc. | N-cyclohexylaminocarbonyl benzenesulfonamide derivatives |
| UA82867C2 (en) | 2003-02-13 | 2008-05-26 | Banyu Pharma Co Ltd | 2-pyridinecarboxamide derivatives |
| KR20050105488A (ko) | 2003-02-26 | 2005-11-04 | 반유 세이야꾸 가부시끼가이샤 | 헤테로아릴카바모일벤젠 유도체 |
| SI1891105T1 (sl) | 2005-06-13 | 2012-07-31 | Imp Innovations Ltd | Analogi oksintomodulina in njihovi učinki na prehranjevalno vedenje |
| EP1991574B1 (en) | 2006-02-22 | 2016-10-12 | Merck Sharp & Dohme Corp. | Oxyntomodulin derivatives |
| EP1999143B1 (en) | 2006-03-20 | 2011-07-13 | Merck Sharp & Dohme Corp. | Neuromedin u receptor agonists and uses thereof |
| EP2049567A2 (en) | 2006-07-18 | 2009-04-22 | Centocor, Inc. | Human glp-1 mimetibodies, compositions, methods and uses |
| BRPI0806789B8 (pt) * | 2007-01-26 | 2021-05-25 | Kaneq Pharma Inc | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo |
| EP2111414B1 (en) | 2007-02-15 | 2014-07-02 | Indiana University Research and Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| US20100179173A1 (en) | 2007-06-28 | 2010-07-15 | Daniel Guay | Substituted fused pyrimidines as antagonists of gpr105 activity |
| WO2009011836A1 (en) | 2007-07-19 | 2009-01-22 | Merck & Co., Inc. | Beta carboline derivatives as antidiabetic compounds |
| US20110301079A1 (en) | 2007-09-21 | 2011-12-08 | Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Neuromedin u receptor agonists and uses thereof |
-
2013
- 2013-04-16 IN IN9640DEN2014 patent/IN2014DN09640A/en unknown
- 2013-04-16 AU AU2013248880A patent/AU2013248880A1/en not_active Abandoned
- 2013-04-16 EP EP13778030.0A patent/EP2838906A4/en not_active Withdrawn
- 2013-04-16 JP JP2015506051A patent/JP2015519309A/ja not_active Withdrawn
- 2013-04-16 WO PCT/CA2013/000364 patent/WO2013155600A1/en not_active Ceased
- 2013-04-16 CA CA2870488A patent/CA2870488A1/en not_active Abandoned
- 2013-04-16 CN CN201380020092.3A patent/CN104411710A/zh active Pending
- 2013-04-16 MX MX2014012465A patent/MX2014012465A/es unknown
- 2013-04-16 KR KR1020147032070A patent/KR20140145624A/ko not_active Withdrawn
- 2013-04-16 US US14/394,503 patent/US20150057220A1/en not_active Abandoned
-
2014
- 2014-10-07 IL IL235081A patent/IL235081A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013155600A1 (en) | 2013-10-24 |
| CA2870488A1 (en) | 2013-10-24 |
| EP2838906A1 (en) | 2015-02-25 |
| JP2015519309A (ja) | 2015-07-09 |
| AU2013248880A1 (en) | 2014-11-06 |
| US20150057220A1 (en) | 2015-02-26 |
| EP2838906A4 (en) | 2015-07-15 |
| KR20140145624A (ko) | 2014-12-23 |
| IL235081A0 (en) | 2014-12-31 |
| MX2014012465A (es) | 2015-01-12 |
| CN104411710A (zh) | 2015-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP17021097A (es) | Compuestos de aminopiridiloxipirazol | |
| CY1121114T1 (el) | Αγωνιστες γλυκαγονης/glp-1 για τη θεραπεια της παχυσαρκιας | |
| CY1122796T1 (el) | Βελτιωμενες φαρμακοτεχνικες μορφες αδενοϊων | |
| MX2018005340A (es) | Proteolisis de direccionamiento a compuestos de quimera y metodos de preparacion y uso de los mismos. | |
| CY1121203T1 (el) | Θεραπευτικες χρησεις της εμπαγλιφλοζινης | |
| SG10201909796PA (en) | Chemosensory receptor ligand-based therapies | |
| MX2015008077A (es) | Derivados de exendina-4 como agonistas dobles de glp1/gip o trigonal de glp1-gip/glucagon. | |
| MY170713A (en) | Treatment protocol of diabetes type 2 | |
| MX2013012896A (es) | Compuestos novedosos como moduladores de proteina cinasas. | |
| PH12015500688A1 (en) | Exendin-4 derivatives as dual glp1/glucagon agonists | |
| EA201400412A1 (ru) | ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ | |
| BR112014026952A2 (pt) | derivados de aminopirimidina pirazol como moduladores lrrk2 | |
| CO6551721A2 (es) | Moduladores de cinasa novedosos | |
| MX356728B (es) | Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2. | |
| JO3366B1 (ar) | مثبطات بيرازوليل كوينوكزالين كاينيز | |
| PH12017500639A1 (en) | Neuroactive compounds and methods of use thereof | |
| MX2020010004A (es) | Composicion farmaceutica que comprende empagliflozina, metodos para tratamiento y sus usos. | |
| MX2013011124A (es) | Compuestos para el tratamiento del sindrome metabolico. | |
| MX2014002159A (es) | Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2. | |
| CO7350641A2 (es) | Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados | |
| MX2013008500A (es) | Disialillacto-n-tetraosa (dslnt) o variantes, isomeros, analogos y derivados de la misma para prevenir o inhibir la enfermedad del intestino. | |
| EA201390616A1 (ru) | ЛЕЧЕНИЕ НАРУШЕНИЙ, АССОЦИИРОВАННЫХ С ГЕНОМ MeCP2 | |
| EA201400623A1 (ru) | Новые 2h-индазолы в качестве антагонистов рецептора ep | |
| CL2014001278A1 (es) | Compuestos triciclicos, inhibidores de proteina quinasa cdc42 de union a proteina quinasa alfa (cdc42bpa o mrcka); composicion farmaceutica; y su uso para tratar una enfermedad, trastorno o condicion seleccionada de obesidad, sobrepeso, distribucion anormal de grasa o cualquier condicion o enfermedad asociada con el mismo. | |
| BR112012008310A2 (pt) | métodos para tratamento de tumores cerebrais |